The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstra	nct		_		1
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b)Provide in the abstract an informative and balanced	X - In title & abstract	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.	X - p2, L 8-14
		summary of what was done and what was found		RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.	X - p2, L 8-14
				RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	X - p2, L 8-14
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	X - p3, L1-45		
Objectives	3	State specific objectives, including any prespecified hypotheses	X - p3, L39-45		
Methods					
Study Design	4	Present key elements of study design early in the paper	X - p4, L3-9		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	X - p4,5		

Participants	6	(a) Cohort study - Give the		RECORD 6.1: The methods of study	
		eligibility criteria, and the		population selection (such as codes or	X - p4, L11-33
		sources and methods of selection		algorithms used to identify subjects)	r ,
		of participants. Describe		should be listed in detail. If this is not	
		methods of follow-up		possible, an explanation should be	
		<i>Case-control study</i> - Give the		provided.	
		eligibility criteria, and the			
		sources and methods of case		RECORD 6.2: Any validation studies	N/A
		ascertainment and control		of the codes or algorithms used to	11/71
		selection. Give the rationale for		select the population should be	
		the choice of cases and controls		referenced. If validation was conducted	
		<i>Cross-sectional study</i> - Give the		for this study and not published	
		eligibility criteria, and the		elsewhere, detailed methods and results	
		sources and methods of selection		should be provided.	
		of participants		should be provided.	
		of participants		RECORD 6.3: If the study involved	
		(b) Cohort study - For matched		linkage of databases, consider use of a	X - p4, L11-33
		studies, give matching criteria		flow diagram or other graphical display	
				to demonstrate the data linkage	
		and number of exposed and		ę	
		unexposed		process, including the number of	
		Case-control study - For		individuals with linked data at each	
		matched studies, give matching		stage.	
		criteria and the number of			
X7 11	7	controls per case			
Variables	7	Clearly define all outcomes,		RECORD 7.1: A complete list of codes	X -p4, L11-33,
		exposures, predictors, potential		and algorithms used to classify	p5, L5-17 &
		confounders, and effect		exposures, outcomes, confounders, and	supplementary
		modifiers. Give diagnostic		effect modifiers should be provided. If	file
		criteria, if applicable.		these cannot be reported, an	
				explanation should be provided.	
Data sources/	8	For each variable of interest,	X - p4,		
measurement		give sources of data and details	L43-46, p5,		
		of methods of assessment	L1-2.		
		(measurement).	-		
		Describe comparability of			
		assessment methods if there is			
		more than one group			

Bias	9	Describe any efforts to address potential sources of bias		X, acknowledged p10,L22-42
Study size	10	Explain how the study size was arrived at		X - p4, L13-16
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why		X - p5, L20-27
Statistical methods	12	 (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity 		X - p5, L30-47, p6, L1-7 X - p5, L10-19 X - p4, L31-33 & p6, L38 X, p6, L12-19
Data access and cleaning methods		analyses 	RECORD 12.1: Authors should describe the extent to which the investigators had access to the database	X, p6, L21-28
			population used to create the study population.	

Linkage			RECORD 12.2: Authors should provide information on the data cleaning methods used in the study. RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	X - p4, L32-35 X - p4, L14-22
Results Participants	13	 (a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non- participation at each stage. (c) Consider use of a flow diagram 	RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	X - p4, L11-33
Descriptive data	14	 (a) Give characteristics of study participants (<i>e.g.</i>, demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i>, average and total amount) 		X - Table 1
Outcome data	15	Cohort study - Report numbers of outcome events or summary measures over time Case-control study - Report numbers in each exposure		X - Figures 1-4

		category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or		
Main results	16	summary measures(a) Give unadjusted estimatesand, if applicable, confounder-adjusted estimates and theirprecision (e.g., 95% confidenceinterval). Make clear whichconfounders were adjusted forand why they were included(b) Report category boundarieswhen continuous variables werecategorized(c) If relevant, considertranslating estimates of relativerisk into absolute risk for ameaningful time period		X - p7, L1-34 Table 2
Other analyses	17	Report other analyses done— e.g., analyses of subgroups and interactions, and sensitivity analyses		X - p6, L36-45 p7 L1-16. Supplementary figures 1-3, table
Discussion			1	2 - 4.
Key results	18	Summarise key results with reference to study objectives		X - p8, L26-38.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	X - p10, L27-47.
Interpretation	20	Give a cautious overall interpretation of results considering objectives,		X - p11, L13-20

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence		
Generalisability	21	Discuss the generalisability (external validity) of the study results		X - p11, L13-20
Other Information	n			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based		X - p6, L25-32
Accessibility of protocol, raw data, and programming code			RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	Restricted access to raw data

*Reference: Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.